About
Titles
Staff Affiliate - Other
Biography
Gloria Huang, MD, is an internationally known expert in the treatment and prevention of ovarian, uterine and cervical cancers. Dr. Huang is skilled at minimally invasive surgery and is the principal investigator of a federally-funded cancer research laboratory. A board-certified gynecologic oncologist, Dr. Huang enjoys providing exceptional, individualized, comprehensive care to patients, bringing together multi-disciplinary clinical teams to achieve the best outcomes. She is passionate about advancing the field of gynecologic oncology through innovative scientific research and hopes her discoveries will lead to better treatments for patients. Watch a video with Dr. Gloria Huang >>
Departments & Organizations
- Discovery to Cure Internship
- Genomics, Genetics, and Epigenetics
- Gynecologic Oncology Program
- Hepatic Arterial Infusion (HAI) Program
- Hyperthermic intraperitoneal chemotherapy (HIPEC) Program
- Obstetrics, Gynecology & Reproductive Sciences
- Oligometastatic Cancer Program
- Reproductive Sciences
- Status of Women in Medicine Committee (SWIM)
- Yale Cancer Center
Education & Training
- Gynecologic Oncology Fellowship
- Albert Einstein College of Medicine (2005)
- Postdoctoral Fellowship
- Stanford University School of Medicine (2002)
- Residency
- Stanford University School of Medicine (2001)
- MD
- Stanford University School of Medicine (1997)
- BS
- Yale University, Biology (1992)
Research
Overview
Endometriosis-associated ovarian cancer
Medical Research Interests
Endometrial Neoplasms; Genital Neoplasms, Female; Genomics; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Ovarian Neoplasms; Pelvic Neoplasms; Uterine Neoplasms
ORCID
0000-0002-0001-888X
Research at a Glance
Yale Co-Authors
Frequent collaborators of Gloria Huang's published research.
Publications Timeline
A big-picture view of Gloria Huang's research output by year.
Research Interests
Research topics Gloria Huang is interested in exploring.
Alessandro Santin, MD
Peter Schwartz, MD
Pei Hui, PhD, MD
Masoud Azodi, MD
Mitchell Clark, MD, MPH
Natalia Buza, MD
87Publications
1,637Citations
Uterine Neoplasms
Ovarian Neoplasms
Endometrial Neoplasms
Genital Neoplasms, Female
Neoplasm Metastasis
Pelvic Neoplasms
Publications
2024
Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.Peer-Reviewed Original ResearchTrastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian cancerClear cell carcinomaHER2-targeting antibody-drug conjugateAntibody-drug conjugatesT-DXdReceptor over-expressionTrastuzumab deruxtecanXenograft modelCell linesOvarian clear cell carcinomaOvarian cancer cell linesTumors overexpressing HER2Biologically aggressive tumorsFluorescence in situ hybridization assaySerous ovarian cancerEffective antibody-drug conjugatesIn vivo antitumor activityMouse xenograft modelMetastatic cell linesDS-8201aCancer cell linesAggressive tumorsHER2 expressionCell carcinomaOvarian cancerRandomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.Peer-Reviewed Original ResearchConceptsPre-treated ovarian cancerOverall survivalBev armsDose reductionOvarian cancerTaxane responseRandomized phase 2 trialRandomized phase II trialPaclitaxel-resistant diseaseResultsThirty-seven patientsTreated with paclitaxelPhase 2 trialBiweekly bevacizumabDays 1,8,15Taxane-sensitiveUpdate survivalProgression-freePeritoneal cancerDose modificationTaxane sensitivityPlatinum resistanceSubset analysisSubgroup analysisResponse ratePatientsARID1A in Gynecologic Precancers and Cancers
Morgan J, Jaferi N, Shonibare Z, Huang G. ARID1A in Gynecologic Precancers and Cancers. Reproductive Sciences 2024, 31: 2150-2162. PMID: 38740655, DOI: 10.1007/s43032-024-01585-w.Peer-Reviewed Original ResearchCitationsConceptsARID1A alterationsGynecologic cancerTumor suppressor ARID1AResponse to chemotherapeutic agentsFrequency of genetic alterationsLoss-of-function mutationsSWI/SNF complex subunitsFemale reproductive tractFunction of ARID1ARadiation therapyTumor-suppressive actionAtypical hyperplasiaARID1A mutationsARID1A deficiencyTherapeutic vulnerabilitiesChemotherapeutic agentsGenetic alterationsImmune modulationClinical evidenceARID1ASignaling pathway interactionsSuppressive actionEndoplasmic reticulumProtein expressionCancerRandomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimodCorrection: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.Peer-Reviewed Original ResearchAltmetric
2023
ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer Staging
AlAshqar A, Mutlu L, McNamara B, Harold J, Clark M, Huang G, Azodi M, Schwartz P, Santin A, Ratner E, Altwerger G, Andikyan V. ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer Staging. Journal Of Minimally Invasive Gynecology 2023, 30: s36. DOI: 10.1016/j.jmig.2023.08.110.Peer-Reviewed Original ResearchConceptsEndometrial cancer stagingSentinel lymph nodesLymph nodesCancer stagingSentinel lymph node identificationICG fluorescence techniqueTertiary care hospitalLymph node identificationICG techniqueSentinel lymphCare hospitalIntervention useStagingDye techniqueNode identificationLymphPatientsMalignancyHospitalIn Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Molecular Cancer Therapeutics 2023, 22: 1404-1412. PMID: 37676984, DOI: 10.1158/1535-7163.mct-23-0126.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsUterine serous carcinomaAntibody-dependent cellular cytotoxicityT-DXdUSC patientsUSC cell linesTrastuzumab deruxtecanSerous carcinomaHER2 expressionClinical trialsRecurrent uterine serous carcinomaTopoisomerase I inhibitor payloadSignificant antibody-dependent cellular cytotoxicityCell linesMultiple tumor indicationsPrimary USC cell linesLow HER2 expressionFuture clinical trialsHigh recurrence ratePeripheral blood lymphocytesERBB2 gene amplificationGrowth suppressionHER2-overexpressing cell linesTumor growth suppressionOverall survivalStandard chemotherapyUterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315)
McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Schlessinger J, Santin A. Uterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315). Gynecologic Oncology 2023, 176: s193. DOI: 10.1016/j.ygyno.2023.06.218.Peer-Reviewed Original ResearchHyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHyperthermic intraperitoneal chemotherapyIntraperitoneal chemotherapyOvarian cancerStage III epithelial ovarian cancerUse of HIPECEpithelial ovarian cancerHigh-quality evidenceOvarian cancer treatmentHIPEC useInterval cytoreductionCytoreductive surgeryNeoadjuvant chemotherapyPerioperative careHIPEC protocolsHIPEC techniqueTreatment modalitiesPatient outcomesSingle administrationTumor disseminationChemotherapyCancerCancer treatmentOptimal candidatesMain siteLife data
Academic Achievements & Community Involvement
activity NRG Oncology
Professional OrganizationsCommittee MemberDetailsGYN Rare Tumor Subcommitee Core Member2018 - Presentactivity Discovery to Cure Internship
Public ServiceMentorDetailsResearch mentorship program for high school students2018 - Presentactivity Committee on the Status of Women in Medicine
CommitteesExecutive Board MemberDetails2021 - Presentactivity Reproductive Sciences
Journal ServiceAssociate EditorDetails2021 - Presentactivity Frontiers in Oncology
Journal ServiceAssociate EditorDetails2021 - Present
News & Links
News
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments
- September 01, 2022Source: Health Extensions
Specialized Team Tackles Gynecologic Cancers
- May 23, 2022Source: CT Insider
Yale Doc: Throat, Neck Cancers Caused by HPV ‘Completely Preventable’ with Caccine
- January 12, 2022
Gloria Huang, MD, in Honor of Cervical Health Awareness Month
Get In Touch
Contacts
Administrative Support
Locations
Division of Gynecologic Oncology
Academic Office
Farnam Memorial Building
310 Cedar Street
New Haven, CT 06510
General Information
203.785.7385Fax
203.737.4377Gloria Huang Lab
Lab
Laboratory for Surgery, Obsterics & Gynecology
375 Congress Avenue, Rm 209
New Haven, CT 06519